95 results
8-K
EX-99.2
SYRS
Syros Pharmaceuticals Inc.
20 Sep 21
Regulation FD Disclosure
4:02pm
Exhibit 99.2
Syros Presents New Data from Phase 1 Trial of SY-5609 and Details Three-Pronged Combination Strategy to Advance SY-5609 in Solid Tumors … ., Chief Medical Officer of Syros. “As we move into this next stage of development, we are introducing a three-pronged strategy to maximize the potential
8-K
EX-99.1
SYRS
Syros Pharmaceuticals Inc.
7 Dec 20
Entry into a Material Definitive Agreement
6:05am
, other than statements of historical facts, contained in this presentation, including statements regarding our strategy, research and clinical development … Capital through multiple expected value drivers into 2H of 2022
Clear vision for SY-1425 in RARA-positive cancers Now Registration strategy in MDS
8-K
EX-99.1
SYRS
Syros Pharmaceuticals Inc.
20 Sep 21
Regulation FD Disclosure
4:02pm
statements, other than statements of historical facts, contained in this presentation, including statements regarding our strategy, research and clinical … cancers Clinical activity was associated with PD marker Data support a three-pronged combination development strategy in solid tumors and in blood cancers
8-K
EX-99.1
SYRS
Syros Pharmaceuticals Inc.
25 Feb 21
Regulation FD Disclosure
7:01am
than statements of historical facts, contained in this presentation, including statements regarding our strategy, research and clinical development … ; Ph3 2022 Expansion 2H 2021
SY-1425 Selective oral RARa agonist
Clear vision for SY-1425 in RARA-positive cancers Now Registration strategy in MDS
8-K
SYRS
Syros Pharmaceuticals Inc.
26 Oct 20
Syros Presents Initial Data from Phase 1 Clinical Trial of SY-5609, Its Selective Oral
6:10am
, other than statements of historical facts, contained in this Form 8-K, including statements regarding the Company’s strategy, research and clinical … establish a patient selection strategy and develop a companion diagnostic test to identify patients most likely to benefit from SY-5609; obtain and maintain
8-K
EX-99.1
karl3wl1
8 Jan 24
Regulation FD Disclosure
7:06am
8-K
EX-99.1
ojvoh5cg
26 May 21
Regulation FD Disclosure
8:30am
8-K
EX-99.1
dr3xtowpcmzu jeqy9lh
12 Dec 22
Regulation FD Disclosure
7:48am
8-K
EX-99.1
mfzawj 1zyp5psvk
7 Jan 19
Regulation FD Disclosure
6:30am
8-K
EX-99.1
sst35rpbgx0t5wlke
24 Apr 19
Regulation FD Disclosure
8:31am
424B3
fm394
27 Jan 21
Prospectus supplement
8:41am
8-K
EX-99.1
g34b8tp5l2v06v9
13 Jan 20
Regulation FD Disclosure
6:11am
8-K
EX-99.1
c2pz vais53iorq7ftnq
2 Dec 19
Regulation FD Disclosure
7:03am
424B5
qat 0e5yw
6 Mar 20
Prospectus supplement for primary offering
5:30pm
8-K
3a0bye071adlgu rgnsa
24 Oct 19
62% Composite Complete Response Rate, with 82% of Patients Achieving or Maintaining Transfusion Independence
8:36am
8-K
EX-99.1
ub9ji7
6 Jul 22
Other Events
4:27pm
8-K
EX-99.1
lqr1o7ldunkhj
13 Feb 20
Syros Announces $60 Million Loan Facility with Oxford Finance LLC
8:51am
8-K
EX-99.1
l6lt54kspu0
25 May 23
Regulation FD Disclosure
5:10pm
8-K
uj5ovxq7k19
17 Oct 19
Syros Announces Update on Selective CDK7 Inhibitor Portfolio
8:30am